1 Under-$10 Stock Set to Surge as Much as 850% in 2026

Core Insights - The biotech sector is attracting savvy investors due to the potential for significant growth, particularly with advancements in artificial intelligence enhancing medical breakthroughs in various therapeutic areas [1] Company Overview - Kura Oncology has transitioned from a clinical-stage to a commercial-stage biotech company following FDA approval of its cancer drug, KOMZIFTI [2][6] - The company is valued at $682.2 billion and focuses on developing targeted small-molecule drugs for cancer treatment [6] Stock Performance and Projections - Kura's stock is down 24% year-to-date, but analysts project a potential surge of up to 850% by 2026 [2] - The average target price for Kura stock is set at $32.45, indicating a potential upside of over 311% from current levels, with a street-high estimate of $76 suggesting an upside of 864% in the next 12 months [4] Market Context - Historical examples in the biotech sector, such as Moderna's 1,227% stock surge due to its COVID-19 vaccine, illustrate the potential for substantial returns when a drug successfully hits the market [5] - Kura's lead drug, KOMZIFTI, addresses a significant unmet need for patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific NPM1 mutation [7]